GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » 9-Day RSI

Biosyent (Biosyent) 9-Day RSI

: 24.86 (As of Today)
View and export this data going back to . Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-18), Biosyent's 9-Day RSI is 24.86.

The industry rank for Biosyent's 9-Day RSI or its related term are showing as below:

BIOYF's 9-Day RSI is ranked better than
56.15% of 1138 companies
in the Drug Manufacturers industry
Industry Median: 41.85 vs BIOYF: 24.86

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent 9-Day RSI Distribution

For the Drug Manufacturers industry and Healthcare sector, Biosyent's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Biosyent's 9-Day RSI falls into.



Biosyent  (OTCPK:BIOYF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Biosyent 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Biosyent's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020